Sickle Cell Matters

Posted: September 10, 2021

It’s Not Just Support. It’s Solutions.


September is National Sickle Cell Awareness Month, a time to acknowledge and educate how this often-invisible and rare disease impacts over 100,000 people in the U.S., most of whom are of African descent. Treatment can include antibiotics, pain management, intravenous fluids, blood transfusion and surgery.

Sickle Cell Disease Association of America (SCDAA) theme for 2021 is Sickle Cell Matters. DiaPharma celebrates the Scientists and Medical Professionals helping to advance knowledge, awareness, and treatment options for Sickle Cell Disease.

Sickle Cell


Tools for Sickle Cell Disease Research

From HbS flow cytometry antibodies, coagulation kits and biomarker assays to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell Research.

Anti-Hemoglobin S antibodies from DiaPharma for flow cytometry applications

Item Clone Description Product Code
Anti-HbS FITC 57-8 Anti-Hemoglobin S antibody conjugated with fluorochrome FITC IQP-574F
Anti-HbF1 Dy-410 WBAC HbF1 Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-410 IQP-567D
Anti-HbF1 FITC WBAC HbF1 Anti-Hemoglobin F antibody conjugated with fluorochrome FITC IQP-567F
Anti-HbF1 R-PE WBAC HbF1 Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE IQP-567R
Anti-panHb APC PHB1 Anti-pan Hemoglobin antibody conjugated with fluorochrome APC IAP-585A

Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established.


Coagulation Markers in Research

It is suggested that aberrant coagulation and platelet overactivation contribute to the pathogenesis of SCD. Further research and clinical trials are needed to explore the mechanisms driving abnormal coagulation in SCD and to identify effective therapies to treat it. DiaPharma offers a range of assays to further SCD research:

Coagulation Factors Components Function Biomarkers and Methods of Evaluation Activity in Sickle Cell Disease
Extrinsic Pathway Tissue factor (TF) FVII Primary pathway to initiate coagulation following vascular endothelial injury Prothrombin time (PT) Increased TF expression
Intrinsic Pathway Prekallikrein HMWK, FXII, FXI Activated by exposed collagen in the subendothelium and functions to initiate clot formation Activated partial thromboplastin time (aPTT) Decreased Prekallikrein, FXII, and HMWK plasma levels
Increased levels of procoagulant microparticles
Common Pathway FV, FVIII, FIX, FX thrombin
Catalysts in the final steps of coagulation to cleave fibrinogen and form blood clots Thrombin Generation Assays (TGA), TAT, PAP, F1.2, D-dimers, fibrinogen Increased thrombin levels
Fibrinolysis Plasmin Enzymatic degradation of fibrin in blood clots uPA, tPA, PAI-1, D-dimers Increased fibrinolytic activity
Platelet Activation Collagen
Fibrinogen, vWF
Platelets activate and aggregate to form a platelet plug vWF, ADAMTS-13, Platelet Function Tests Increased platelet numbers, platelet activation, and platelet aggregation
Complement System C3a
Activated by the coagulation system and contributes to thrombus formation C3a and C5a Increased C3a and C5a expression
Anticoagulation Proteins Protein C
Protein S
Negative feedback to regulate coagulation and inflammation Protein C
Protein S
Decreased Protein C and Protein S levels


Automated Measurement of Primary and Secondary Hemostasis Markers

Instrument Fully Automated Coagulation Analyzer Clot Growth & Fibrinolysis Dynamics Primary Hemostasis and Platelet Function Testing
Ceveron® 100 Series Thrombodynamics T-TAS® 01 Atlas PST

Ceveron® series, Thrombodynamics®, and Atlas® PST are for research use only. Not for use in diagnostic procedures.

It’s Not Just Support. It’s Solutions.

Over 20 years of scientific expertise, with support just a call or click away.

diapharma bioassays


Copyright © 2021 DiaPharma Group, Inc. All rights reserved.

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846